Amla (10:1 Extract): What the Research Shows, and What Turned Out to Be a Legend

In Brief

Amla, the Indian gooseberry, is a fruit surrounded by dense mythology. It is a rare case where legend and evidence run in parallel and barely meet: what gets repeated most does not survive checking, and what is actually proven is barely mentioned.

Start with the legend, because it is the famous part.

Vitamin C: Where the «Twenty Times» Came From

The line «amla has twenty times more vitamin C than an orange» is repeated so often it has become background noise. It takes one pass to check.

The only sound comparison is one where both fruits are measured by the same laboratory, by the same method, and published in the same book. The Indian food composition tables do exactly that: amla 252 mg per 100 g, orange 42.7 mg. A 5.9-fold difference. Take the USDA figure for orange, 53 mg, and the gap is smaller still — 4.7-fold.

So where does twenty come from? From an older value of 600 mg per 100 g, published in 1951 and copied from source to source ever since. The same book that reports the modern measurement of 252 mg cites the 1951 figure as a historical note, not as its own finding.

The spread across sources is enormous: published values for fresh fruit range from 155 to 600 mg per 100 g, nearly fourfold. Any ratio depends on which number you take — which is exactly why it cannot be presented as a fact without naming the source.

And a separate caveat, which concerns the jar rather than the fruit: there is not a single measurement of vitamin C in a dried amla extract. How much survives drying and storage is unknown. So even the correct ratio describes fresh fruit, not a capsule.

Six times is still a lot. It is simply true, and twenty is not.

What Is Actually Proven: Lipids

Here the picture reverses: there is more evidence than you would expect from a botanical supplement.

A meta-analysis of nine randomised trials in 535 participants exists. Doses ranged from 500 to 1500 mg a day, duration from two to twelve weeks.

Three things must be read alongside that table.

On HDL-C. No effect is proven, and this matters because the discussion section of that same paper mistakenly lists HDL-C among the significant results. The results section is the one to trust. A second meta-analysis reaches the opposite conclusion on this measure — so the question is open.

On heterogeneity. For LDL-C the trials disagree with each other considerably, and the prediction interval — the range a result would fall into in a new population — crosses zero. Put plainly: on average there is an effect, but in an individual it may be none.

On quality. Not one of the nine included trials was rated at low risk of bias. Seven of the nine were conducted in India and four came from a single research group, so the data are less independent than the count suggests. Publication bias could not be assessed: too few studies.

The C-reactive protein result deserves separate mention. Heterogeneity there is zero — the inflammation finding is more robust than the lipid one, though it gets discussed far less.

Blood Sugar and Other Directions

• Fasting glucose — a reduction is confirmed in meta-analysis, but the size of the effect cannot be stated: the available publication reports significance levels only.
• HbA1c — no pooled estimate exists at all. Individual small trials exist; a general conclusion does not.
• Endothelial function — one double-blind trial in 59 participants with metabolic syndrome, on a surrogate measure, funded by the manufacturer.
• Body weight — no placebo-controlled trials were found.

That is the honest picture: lipids and inflammation are reasonably studied, everything else rests on scattered work of varying quality.

What the 10:1 Ratio Means

An extract is more effective than a powder, and the reason is concentration. A 10:1 ratio means ten parts of raw material yield one part of preparation. A capsule of extract carries more active compounds than the same weight of simply dried and ground fruit, which is why extract doses differ from powder doses.

But there is a caveat without which a reader will miscalculate. The ratio cannot be converted into trial doses. No clinical study of amla used a 10:1 extract. Trials standardised differently — by polyphenol content (at least 35%), by ellagitannins (1.2–1.5%), by hydrolysable tannins (at least 60%) — that is, by active compounds. The ratio tells you how much raw material went into a gram of extract; it says nothing about how much active substance ended up there, which depends on cultivar, ripeness, solvent and drying.

It is also worth knowing that under European rules for herbal preparations the correct way to state a ratio is as a range, such as «5–8:1», because extraction yield varies between batches. A round «10:1» on a label is a consumer-facing form, not a pharmaceutical characteristic.

The practical conclusion: follow the manufacturer's dosing rather than trying to convert capsules into grams of fruit from a study.

Safety: Mainly About Blood

Clotting. Amla has a demonstrated antiplatelet effect in humans. In a clinical study it prolonged bleeding time and — this is the key detail — the effect was not abolished by concurrent clopidogrel or aspirin. It adds to them rather than dissolving into them. The study was small and open-label, but it is the only direct evidence on this interaction, and it cannot be waved away.

Anticoagulants. With warfarin, heparin and the direct oral anticoagulants amla has not been studied at all: no trials, no case reports. Absence of data here is not evidence of safety — it is absence of data.

Glucose-lowering drugs. Amla measurably lowers fasting glucose. The combination has not been studied in people; the risk of additive lowering is theoretical, but it rests on a real effect rather than on speculation.

Surgery. Because of the effect on clotting, discuss the supplement with your doctor in advance and expect to stop it some days before planned surgery.

Pregnancy and breastfeeding. No data, so it is not used.

Who It Makes Sense For

The Bottom Line

Amla is a rare case of a supplement whose evidence is worse than its reputation in one respect and better in another. Worse, because the best-known claim about it — twentyfold vitamin C — does not survive checking. Better, because a meta-analysis of nine randomised trials exists, and it shows real reductions in LDL-C, triglycerides and a marker of inflammation.

The effect size is modest: fifteen milligrams per decilitre of LDL-C is roughly a tenth of what an average statin dose delivers. It cannot replace a medicine, and promising that would be dishonest. Complementing lifestyle measures, and — if your doctor agrees — therapy, is within reach. What works for raised cholesterol beyond supplements, and when statins are genuinely needed, is covered separately: cholesterol without statins.

The thing most worth remembering, and the thing least often written: amla affects blood clotting, and with blood-thinning medicines its action adds to theirs. If you take those, this is a conversation with your doctor before the first capsule, not after.